Novo Nordisk A/S (NONOF)
USD 69.9
(6.72%)
USD 69.9
(6.72%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 232.26 Billion DKK | 31.26% |
| 2022 | 176.95 Billion DKK | 25.68% |
| 2021 | 140.8 Billion DKK | 10.91% |
| 2020 | 126.94 Billion DKK | 4.04% |
| 2019 | 122.02 Billion DKK | 9.11% |
| 2018 | 111.83 Billion DKK | 0.12% |
| 2017 | 111.69 Billion DKK | -0.08% |
| 2016 | 111.78 Billion DKK | 3.57% |
| 2015 | 107.92 Billion DKK | 21.53% |
| 2014 | 88.8 Billion DKK | 6.26% |
| 2013 | 83.57 Billion DKK | 7.11% |
| 2012 | 78.02 Billion DKK | 17.6% |
| 2011 | 66.34 Billion DKK | 9.16% |
| 2010 | 60.77 Billion DKK | 18.99% |
| 2009 | 51.07 Billion DKK | 11.85% |
| 2008 | 45.66 Billion DKK | 9.02% |
| 2007 | 41.88 Billion DKK | 8.09% |
| 2006 | 38.75 Billion DKK | 14.94% |
| 2005 | 33.71 Billion DKK | 15.33% |
| 2004 | 29.23 Billion DKK | 9.85% |
| 2003 | 26.61 Billion DKK | 5.8% |
| 2002 | 25.15 Billion DKK | 6.06% |
| 2001 | 23.71 Billion DKK | 13.94% |
| 2000 | 20.81 Billion DKK | -0.62% |
| 1999 | 20.94 Billion DKK | 16.94% |
| 1998 | 17.9 Billion DKK | 5.45% |
| 1997 | 16.98 Billion DKK | 13.96% |
| 1996 | 14.9 Billion DKK | 8.68% |
| 1995 | 13.71 Billion DKK | 1.44% |
| 1994 | 13.51 Billion DKK | 2.83% |
| 1993 | 13.14 Billion DKK | 23.19% |
| 1992 | 10.67 Billion DKK | 8.56% |
| 1991 | 9.82 Billion DKK | 17.97% |
| 1990 | 8.33 Billion DKK | 9.36% |
| 1989 | 7.61 Billion DKK | 35.34% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 65.34 Billion DKK | -0.78% |
| 2024 Q2 | 68.06 Billion DKK | 4.15% |
| 2023 FY | 232.26 Billion DKK | 31.26% |
| 2023 Q3 | 58.73 Billion DKK | 8.16% |
| 2023 Q4 | 65.86 Billion DKK | 12.14% |
| 2023 Q1 | 53.36 Billion DKK | 10.97% |
| 2023 Q2 | 54.3 Billion DKK | 1.75% |
| 2022 Q1 | 42.03 Billion DKK | 9.65% |
| 2022 Q3 | 45.56 Billion DKK | 10.42% |
| 2022 FY | 176.95 Billion DKK | 25.68% |
| 2022 Q2 | 41.26 Billion DKK | -1.82% |
| 2022 Q4 | 48.09 Billion DKK | 5.54% |
| 2021 Q3 | 35.62 Billion DKK | 7.81% |
| 2021 Q4 | 38.33 Billion DKK | 7.61% |
| 2021 Q1 | 33.8 Billion DKK | 5.18% |
| 2021 Q2 | 33.04 Billion DKK | -2.26% |
| 2021 FY | 140.8 Billion DKK | 10.91% |
| 2020 Q4 | 32.13 Billion DKK | 3.92% |
| 2020 Q2 | 30 Billion DKK | -11.42% |
| 2020 Q1 | 33.87 Billion DKK | 4.5% |
| 2020 Q3 | 30.92 Billion DKK | 3.07% |
| 2020 FY | 126.94 Billion DKK | 4.04% |
| 2019 Q4 | 32.41 Billion DKK | 7.07% |
| 2019 Q1 | 29.29 Billion DKK | -1.48% |
| 2019 Q2 | 30.03 Billion DKK | 2.54% |
| 2019 Q3 | 30.27 Billion DKK | 0.8% |
| 2019 FY | 122.02 Billion DKK | 9.11% |
| 2018 Q2 | 27.4 Billion DKK | 1.77% |
| 2018 Q4 | 29.73 Billion DKK | 7.1% |
| 2018 Q1 | 26.93 Billion DKK | -3.79% |
| 2018 FY | 111.83 Billion DKK | 0.12% |
| 2018 Q3 | 27.76 Billion DKK | 1.3% |
| 2017 Q3 | 26.61 Billion DKK | -7.07% |
| 2017 FY | 111.69 Billion DKK | -0.08% |
| 2017 Q2 | 28.63 Billion DKK | 0.65% |
| 2017 Q4 | 27.99 Billion DKK | 5.18% |
| 2017 Q1 | 28.45 Billion DKK | -3.79% |
| 2016 Q3 | 27.53 Billion DKK | 0.28% |
| 2016 Q4 | 29.57 Billion DKK | 7.39% |
| 2016 Q1 | 27.21 Billion DKK | -5.76% |
| 2016 Q2 | 27.45 Billion DKK | 0.91% |
| 2016 FY | 111.78 Billion DKK | 3.57% |
| 2015 Q4 | 28.87 Billion DKK | 7.78% |
| 2015 Q3 | 26.79 Billion DKK | -0.99% |
| 2015 Q1 | 25.2 Billion DKK | 2.5% |
| 2015 Q2 | 27.05 Billion DKK | 7.38% |
| 2015 FY | 107.92 Billion DKK | 21.53% |
| 2014 Q3 | 22.24 Billion DKK | 2.87% |
| 2014 FY | 88.8 Billion DKK | 6.26% |
| 2014 Q1 | 20.34 Billion DKK | -6.24% |
| 2014 Q2 | 21.62 Billion DKK | 6.32% |
| 2014 Q4 | 24.58 Billion DKK | 10.5% |
| 2013 Q4 | 21.69 Billion DKK | 5.79% |
| 2013 FY | 83.57 Billion DKK | 7.11% |
| 2013 Q1 | 19.98 Billion DKK | -4.67% |
| 2013 Q2 | 21.38 Billion DKK | 6.99% |
| 2013 Q3 | 20.51 Billion DKK | -4.06% |
| 2012 Q1 | 17.75 Billion DKK | -2.04% |
| 2012 Q4 | 20.96 Billion DKK | 5.63% |
| 2012 FY | 78.02 Billion DKK | 17.6% |
| 2012 Q3 | 19.84 Billion DKK | 1.94% |
| 2012 Q2 | 19.46 Billion DKK | 9.67% |
| 2011 FY | 66.34 Billion DKK | 9.16% |
| 2011 Q2 | 16 Billion DKK | 1.96% |
| 2011 Q3 | 16.53 Billion DKK | 3.32% |
| 2011 Q4 | 18.12 Billion DKK | 9.61% |
| 2011 Q1 | 15.69 Billion DKK | -2.67% |
| 2010 Q1 | 13.67 Billion DKK | 4.69% |
| 2010 Q2 | 15.39 Billion DKK | 12.58% |
| 2010 Q3 | 15.58 Billion DKK | 1.23% |
| 2010 Q4 | 16.12 Billion DKK | 3.47% |
| 2010 FY | 60.77 Billion DKK | 18.99% |
| 2009 FY | 51.07 Billion DKK | 11.85% |
| 2009 Q3 | 12.51 Billion DKK | -3.72% |
| 2009 Q2 | 13 Billion DKK | 4.02% |
| 2009 Q1 | 12.49 Billion DKK | -1.77% |
| 2009 Q4 | 13.06 Billion DKK | 4.35% |
| 2008 Q4 | 12.72 Billion DKK | 13.23% |
| 2008 FY | 45.66 Billion DKK | 9.02% |
| 2008 Q2 | 11.11 Billion DKK | 4.8% |
| 2008 Q1 | 10.6 Billion DKK | -3.73% |
| 2008 Q3 | 11.23 Billion DKK | 1.11% |
| 2007 Q2 | 10.56 Billion DKK | 7.64% |
| 2007 Q4 | 11.01 Billion DKK | 4.92% |
| 2007 FY | 41.88 Billion DKK | 8.09% |
| 2007 Q1 | 9.81 Billion DKK | -6.35% |
| 2007 Q3 | 10.49 Billion DKK | -0.65% |
| 2006 Q1 | 8.95 Billion DKK | -4.75% |
| 2006 FY | 38.75 Billion DKK | 14.94% |
| 2006 Q4 | 10.48 Billion DKK | 9.34% |
| 2006 Q2 | 9.73 Billion DKK | 8.72% |
| 2006 Q3 | 9.58 Billion DKK | -1.48% |
| 2005 Q4 | 9.39 Billion DKK | 6.91% |
| 2005 FY | 33.71 Billion DKK | 15.33% |
| 2005 Q3 | 8.78 Billion DKK | 6.26% |
| 2005 Q2 | 8.27 Billion DKK | 13.86% |
| 2005 Q1 | 7.26 Billion DKK | -9.2% |
| 2004 Q4 | 8 Billion DKK | 7.21% |
| 2004 FY | 29.23 Billion DKK | 9.85% |
| 2004 Q3 | 7.46 Billion DKK | 8.19% |
| 2004 Q1 | 6.52 Billion DKK | -10.06% |
| 2004 Q2 | 6.89 Billion DKK | 5.71% |
| 2003 Q1 | 6.09 Billion DKK | -8.86% |
| 2003 Q4 | 7.25 Billion DKK | 8.07% |
| 2003 Q3 | 6.71 Billion DKK | 3.56% |
| 2003 FY | 26.61 Billion DKK | 5.8% |
| 2003 Q2 | 6.48 Billion DKK | 6.45% |
| 2002 Q1 | 6.02 Billion DKK | -7.42% |
| 2002 Q2 | 5.27 Billion DKK | -12.32% |
| 2002 Q3 | 6.44 Billion DKK | 22.11% |
| 2002 Q4 | 6.68 Billion DKK | 3.67% |
| 2002 FY | 25.15 Billion DKK | 6.06% |
| 2001 Q1 | 5.34 Billion DKK | 146.84% |
| 2001 FY | 23.71 Billion DKK | 13.94% |
| 2001 Q4 | 6.5 Billion DKK | -2.24% |
| 2001 Q3 | 6.65 Billion DKK | 15.78% |
| 2001 Q2 | 5.74 Billion DKK | 7.47% |
| 2000 Q2 | 6.48 Billion DKK | 16.57% |
| 2000 Q3 | 15.34 Billion DKK | 136.62% |
| 2000 FY | 20.81 Billion DKK | -0.62% |
| 2000 Q4 | 2.16 Billion DKK | -85.88% |
| 2000 Q1 | 5.56 Billion DKK | 0.01% |
| 1999 Q2 | 5.02 Billion DKK | 8.45% |
| 1999 Q4 | 5.56 Billion DKK | -4.48% |
| 1999 FY | 20.94 Billion DKK | 16.94% |
| 1999 Q1 | 4.63 Billion DKK | -5.0% |
| 1999 Q3 | 5.82 Billion DKK | 15.94% |
| 1998 Q2 | 4.56 Billion DKK | 8.95% |
| 1998 Q1 | 4.19 Billion DKK | -10.56% |
| 1998 Q4 | 4.87 Billion DKK | -3.17% |
| 1998 FY | 17.9 Billion DKK | 5.45% |
| 1998 Q3 | 5.03 Billion DKK | 10.22% |
| 1997 Q4 | 4.68 Billion DKK | 8.61% |
| 1997 Q2 | 4.12 Billion DKK | 13.72% |
| 1997 Q1 | 3.62 Billion DKK | -13.67% |
| 1997 FY | 16.98 Billion DKK | 13.96% |
| 1997 Q3 | 4.31 Billion DKK | 4.63% |
| 1996 FY | 14.9 Billion DKK | 8.68% |
| 1996 Q4 | 4.2 Billion DKK | 14.51% |
| 1996 Q3 | 3.66 Billion DKK | 4.6% |
| 1996 Q2 | 3.5 Billion DKK | 2.12% |
| 1996 Q1 | 3.43 Billion DKK | 0.7% |
| 1995 FY | 13.71 Billion DKK | 1.44% |
| 1995 Q4 | 3.41 Billion DKK | 6.0% |
| 1995 Q3 | 3.21 Billion DKK | -9.94% |
| 1995 Q2 | 3.57 Billion DKK | 6.01% |
| 1995 Q1 | 3.37 Billion DKK | -5.24% |
| 1994 Q1 | 3.11 Billion DKK | -26.64% |
| 1994 FY | 13.51 Billion DKK | 2.83% |
| 1994 Q4 | 3.55 Billion DKK | 5.4% |
| 1994 Q3 | 3.37 Billion DKK | -1.4% |
| 1994 Q2 | 3.42 Billion DKK | 10.02% |
| 1993 Q4 | 4.24 Billion DKK | 35.46% |
| 1993 Q2 | 3 Billion DKK | 14.37% |
| 1993 Q3 | 3.13 Billion DKK | 4.25% |
| 1993 Q1 | 2.62 Billion DKK | -3.24% |
| 1993 FY | 13.14 Billion DKK | 23.19% |
| 1992 Q2 | 2.8 Billion DKK | 5.54% |
| 1992 Q1 | 2.66 Billion DKK | -9.6% |
| 1992 Q4 | 2.71 Billion DKK | 5.79% |
| 1992 FY | 10.67 Billion DKK | 8.56% |
| 1992 Q3 | 2.56 Billion DKK | -8.67% |
| 1991 Q4 | 2.94 Billion DKK | 23.05% |
| 1991 Q1 | 2.27 Billion DKK | -2.13% |
| 1991 Q2 | 2.24 Billion DKK | -1.2% |
| 1991 Q3 | 2.39 Billion DKK | 6.4% |
| 1991 FY | 9.82 Billion DKK | 17.97% |
| 1990 Q3 | 2.02 Billion DKK | -0.11% |
| 1990 Q4 | 2.32 Billion DKK | 14.61% |
| 1990 Q2 | 2.03 Billion DKK | 4.7% |
| 1990 FY | 8.33 Billion DKK | 9.36% |
| 1990 Q1 | 1.94 Billion DKK | -9.53% |
| 1989 Q3 | 1.74 Billion DKK | -0.53% |
| 1989 Q1 | 1.97 Billion DKK | 20.78% |
| 1989 Q2 | 1.75 Billion DKK | -11.07% |
| 1989 Q4 | 2.14 Billion DKK | 22.72% |
| 1989 FY | 7.61 Billion DKK | 35.34% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioxytran, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -1472422.665% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -1081290.26% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -353366806.037% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -1274798.452% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -188801.002% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 645.81 Thousand USD | -35964192.903% |
| Genus plc | 668.8 Million USD | -34628.02% |
| Pharming Group N.V. | 245.31 Million USD | -94578.292% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -234621190.179% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -56626135.783% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -302576729.38% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -587734603.173% |
| ONE Bio Corp. | 52.29 Million USD | -444025.934% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -467028.577% |
| Mesoblast Limited | 5.9 Million USD | -3935193.121% |
| MultiCell Technologies, Inc. | 49.32 USD | -470926601684.266% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -784645.076% |
| Genscript Biotech Corporation | 839.52 Million USD | -27565.632% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -1318091949.259% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -41645378.833% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -331801328.571% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -306720358.507% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -35271122.475% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -474971270.143% |
| Q BioMed Inc. | 284.35 Thousand USD | -81680704.074% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | -1481.082% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -159970.019% |
| Enzolytics Inc. | 52.79 Thousand USD | -439921484.969% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -38167764.919% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | -18839.735% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -12021690.89% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -23249349249.349% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -165614337.9% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -37620084.52% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -23278936.529% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -480234.616% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -1391900.973% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -98182602.063% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -98182602.063% |
| Affymax, Inc. | 1.36 Million USD | -16965641.417% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -2981810.386% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -49028038.391% |
| SYBLEU INC | 11.69 Thousand USD | -1985815563.475% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -1786622976.923% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -587496738.165% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -6974704.805% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -3484686.197% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -22354182.964% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -901289.374% |
| CSL Limited | 14.8 Billion USD | -1469.331% |
| Cellectis S.A. | 755 Thousand USD | -30762946.358% |